Regeneron (REGN) jumps on robust Q4 earnings

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) jumped more than 5% in pre-market trading Friday after the pharma company posted better-than-anticipated Q4 earnings.

Regeneron reported adjusted earnings per share (EPS) of $11.86 for the fourth quarter, beating the consensus projection of $10.62. Revenue came in at $3.43 billion, while analysts were looking for $3.27 billion.

The company generated $1.34 billion in Eylea net sales, falling short of Wall Street’s expectations of $1.46 billion. Dupixent brought $2.49 billion in net sales, just above the estimated $2.47 billion.

For the full fiscal year, Regeneron anticipates its research and development (R&D) expenses will range between $4.82 billion and $5.07 billion, and its selling, general, and administrative (SG&A) expenses are expected to be between $2.89 billion and $3.09 billion. The company also forecasts an effective tax rate of 8% to 10%.

"We were pleased with our fourth-quarter and full-year 2023 financial performance, highlighted by revenue growth of 14% and 12%, respectively, when excluding contributions from Ronapreve, reflecting continued strength across our business," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron.

By Vahid Karaahmetovic

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• FDA selects 7 companies for domestic drug manufacturing pilot
• Contango settles $18.75M Lucky Shot obligations for $6.57M